Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · March 02, 2023

Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes

Circulation

 

Additional Info

Circulation
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
Circulation 2023 Feb 20;[EPub Ahead of Print], HC Gerstein, Z Li, C Ramasundarahettige, S Baek, KRH Branch, S Del Prato, CSP Lam, RD Lopes, R Pratley, J Rosenstock, N Sattar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading